Medical News

RSS

Protein p62 acts as molecular brake to keep inflammation in check, avoid collateral damage

Inflammation is a Catch-22: the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and sometimes leading to organ failure and death. Researchers at University of California, San Diego School of Medicine have discovered that a protein known as p62 acts as a molecular brake to keep inflammation in check and avoid collateral damage.

26 Feb 2016

New infection-fighting bandages for serious burn victims

Serious burn victims are immunocompromised and may be missing skin on parts of their body, and this makes them highly vulnerable to bacteria. Thanks to progress in intensive care, they are decreasingly likely to die from burn trauma. Death is more commonly the result of infections that can occur several months after being hospitalized. The bandages used to treat burns actually represent a real breeding ground for microbes.

26 Feb 2016

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.

26 Feb 2016

Study shows high cost, high side effects and little gain for chemotherapy in older mCRC patients

A study published online ahead of print in the journal Medical Care shows that over a recent 10-year period, the rate of metastatic colorectal cancer patients older than age 75 receiving three or more treatments increased from 2 percent to 53 percent.

26 Feb 2016

Genome sequencing shows association between STIs and Trachoma

For the first time, genome sequencing has been carried out on Chlamydia trachomatis (C. trachomatis), a bacteria responsible for the disease Trachoma - the world's leading infectious cause of blindness, according to a study in Nature Communications.

26 Feb 2016

Japanese bioengineers tweak E. coli genes to pump out morphine precursor

A common gut microbe could soon be offering us pain relief. Japanese bioengineers have tweaked Escherichia coli genes so that they pump out thebaine, a morphine precursor that can be modified to make painkillers. The genetically modified E. coli produces 300 times more thebaine with minimal risk of unregulated use compared to a recently developed method involving yeast.

26 Feb 2016

New review suggests solutions that can help ease chronic pain in women

Women often suffer silently when in pain, whether it's caused by pregnancy discomfort or creaky knees. Yet there are a variety of solutions that can help relieve women of chronic pain, from exercise to identifying triggers, suggests a new review of research related to women and pain by the American Society of Anesthesiologists.

26 Feb 2016

Research finding could lay foundation for more accurate diagnosis for rare childhood brain tumor

An international research team has identified four likely new subtypes of a rare brain tumor using molecular techniques that lay the foundation for more accurate diagnosis and tailored therapies for the hard-to-treat cancer. Scientists at St. Jude Children's Research Hospital and the German Cancer Research Center led the study, results of which appear today in the scientific journal Cell.

26 Feb 2016

Medical community has unique role to play in determining future use of mitochondrial replacement techniques

There is a unique role for the United States medical community to play in determining the future application of, and ethically acceptable approach to, mitochondrial replacement techniques (MRTs), according to a commentary published online by the New England Journal of Medicine.

26 Feb 2016

Black men have higher rate and probability of PSA screening compared to non-Hispanic whites

African American men have the highest rate of prostate cancer and shorter survival time compared to other racial/ethnic groups in the U.S. Their mortality rate is more than twice that of their white counterparts. Early diagnosis through PSA screening may help forestall consequent morbidity and mortality.

26 Feb 2016

Aggregated forms of transthyretin can trigger JIA development

Juvenile idiopathic arthritis (JIA) is a the most common form of arthritis in children and affects approximately 50,000 individuals in the United States alone. Previous research suggested that autoimmune responses cause JIA, but the specific antigens that are responsible for driving autoimmunity have not been identified.

26 Feb 2016

Kansas State University engineers developing technology to help children with special needs

A Kansas State University engineering team is developing a technology collection that can make a big difference in the lives of children with developmental disabilities.

26 Feb 2016

Scientists develop new optical technique to observe neurotransmitter activity of individual synapses

Columbia University scientists have developed a new optical technique to study how information is transmitted in the brains of mice. Using this method, they found that only a small portion of synapses -- the connections between cells that control brain activity--may be active at any given time.

26 Feb 2016

New Notre Dame research may lead to a therapy for Niemann-Pick Type C disease

Niemann-Pick Type C (NPC) disease is a rare, fatal neurodegenerative disease for which there is currently no cure. NPC primarily strikes children before and during adolescence and affects one in every 150,000 children. The disease causes cholesterol and other lipids to build up in the body's cells, which results in symptoms such as delayed motor development, deterioration of memory and balance, and seizures.

26 Feb 2016

Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

In a small, placebo-controlled clinical trial, Johns Hopkins physicians report that the antidepressant paroxetine modestly improves decision-making and reaction time, and suppresses inflammation in people with HIV-associated cognitive impairment. The researchers say they believe this is the first time that a SSRI (selective serotonin reuptake inhibitor) has been shown to improve key measures of cognition in people with HIV in a controlled study.

26 Feb 2016

Chubb named top 2015 New-Product Pacesetter by Advisen for contributions in product innovation

Chubb has been named the top 2015 New-Product Pacesetter by Advisen, an insurance news source for the insurance industry, for its contributions in product innovation.

26 Feb 2016

Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Allergan plc, a leading global pharmaceutical company, today announced that the Company has received approval from the U.S. Food and Drug Administration to market ACZONE (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older.

26 Feb 2016

Clinical validation study on MaterniT GENOME test published in American Journal of Obstetrics and Gynecology

Sequenom, Inc., a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the publication of a clinical validation study on the MaterniT GENOME laboratory-developed test in the American Journal of Obstetrics and Gynecology.

26 Feb 2016

China Biologic's total sales increase by 22.6% in RMB terms to $68.3 million in Q4 2015

China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2015.

26 Feb 2016

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

26 Feb 2016

Medical News

Protein p62 acts as molecular brake to keep inflammation in check, avoid collateral damage

New infection-fighting bandages for serious burn victims

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Study shows high cost, high side effects and little gain for chemotherapy in older mCRC patients

Genome sequencing shows association between STIs and Trachoma

Japanese bioengineers tweak E. coli genes to pump out morphine precursor

New review suggests solutions that can help ease chronic pain in women

Research finding could lay foundation for more accurate diagnosis for rare childhood brain tumor

Medical community has unique role to play in determining future use of mitochondrial replacement techniques

Black men have higher rate and probability of PSA screening compared to non-Hispanic whites

Aggregated forms of transthyretin can trigger JIA development

Kansas State University engineers developing technology to help children with special needs

Scientists develop new optical technique to observe neurotransmitter activity of individual synapses

New Notre Dame research may lead to a therapy for Niemann-Pick Type C disease

Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

Chubb named top 2015 New-Product Pacesetter by Advisen for contributions in product innovation

Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Clinical validation study on MaterniT GENOME test published in American Journal of Obstetrics and Gynecology

China Biologic's total sales increase by 22.6% in RMB terms to $68.3 million in Q4 2015

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News